These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 32230938)

  • 21. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
    Ferraresi V; Vari S
    Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
    Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
    BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regarding "Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18".
    da Costa AABA; Souza RP; Pandolfi NC; de Souza Castro F; Baiocchi G; Guimarães APG
    Gynecol Oncol; 2024 Oct; 189():109-110. PubMed ID: 39084160
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
    Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
    D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
    Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.
    Longoria TC; Tewari KS
    Drugs; 2015 Nov; 75(16):1853-65. PubMed ID: 26474780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.
    Cui R; Li Y; Yu X; Wei C; Jiang O
    PLoS One; 2024; 19(6):e0304941. PubMed ID: 38865375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
    Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
    World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
    O'Malley DM; Randall LM; Jackson CG; Coleman RL; Hays JL; Moore KN; Naumann RW; Rocconi RP; Slomovitz BM; Tewari KS; Ancukiewicz M; Feliu WO; Monk BJ
    Future Oncol; 2021 Sep; 17(26):3433-3443. PubMed ID: 34409858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing immunotherapy for gynecologic cancers.
    Rubinstein MM; Makker V
    Curr Opin Obstet Gynecol; 2020 Feb; 32(1):1-8. PubMed ID: 31833942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.
    Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P
    Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
    Liu C; Ran X; Wang Z; Zhang K
    Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?
    Splendiani E; Besharat ZM; Covre A; Maio M; Di Giacomo AM; Ferretti E
    Pharmacol Ther; 2024 Apr; 256():108613. PubMed ID: 38367867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma.
    Marconcini R; Pezzicoli G; Stucci LS; Sergi MC; Lospalluti L; Porta C; Tucci M
    Hum Vaccin Immunother; 2022 May; 18(3):1980315. PubMed ID: 34613889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.